Related Experiment Video
Updated: Jan 21, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
High expression of NFAT2 contributes to carboplatin resistance in lung cancer
Xi Liu1, Chun-Guo Pan2, Zhi-Qiang Luo2
1Thoracic Surgery, Jiangxi Cancer Hospital, Nanchang, Jiangxi 330029, PR China.
Abstract:
Carboplatin is a platinum-based chemotherapy drug in lung cancer treatment. However, its efficacy is frequently limited by intrinsic and acquired drug resistance. Recently, nucleus factor of activated T cells, cytoplasmic 1 (NFAT2) has been recognized as an oncogene and involved in disease progression and drug resistance in various cancers. In the current study, we found that overexpression of NFAT2 was associated with poor prognosis in lung cancer patients, and is observed in a carboplatin resistant lung cancer cell line, indicative of its role in regulating drug response. We further showed that NFAT2 played a critical role in promoting cell proliferation and overcome carboplatin-induced DNA damage and cell cycle arrest. NFAT2 knockdown or inhibition of its nucleus translation via cyclosporine A largely restored the sensitivity to carboplatin in the resistant line by inducing DNA damage, blocking cell cycle progression and activating apoptotic cell death. We thus suggest that NFAT2 is a putative therapeutic target to overcome carboplatin resistance in lung cancers.
Insights
Nuclear factor of activated T cells, cytoplasmic 1 (NFAT2) drives carboplatin resistance in lung cancer. Inhibiting NFAT2 may restore chemotherapy sensitivity, offering a new therapeutic target for lung cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Carboplatin is a key chemotherapy for lung cancer.
- Drug resistance limits carboplatin's effectiveness.
- Nuclear factor of activated T cells, cytoplasmic 1 (NFAT2) is an emerging oncogene implicated in cancer progression and drug resistance.
Purpose of the Study:
- To investigate the role of NFAT2 in carboplatin resistance in lung cancer.
- To determine if NFAT2 is a viable therapeutic target for overcoming carboplatin resistance.
Main Methods:
- Analysis of NFAT2 expression in lung cancer patients and cell lines.
- Assessment of NFAT2's impact on cell proliferation, DNA damage, and cell cycle.
- Evaluation of carboplatin sensitivity following NFAT2 knockdown or inhibition using cyclosporine A.
Main Results:
- Overexpressed NFAT2 correlates with poor prognosis in lung cancer patients.
- NFAT2 is overexpressed in carboplatin-resistant lung cancer cells.
- NFAT2 promotes proliferation and resistance to carboplatin-induced DNA damage and cell cycle arrest.
- NFAT2 inhibition restores carboplatin sensitivity by increasing DNA damage, blocking cell cycle, and inducing apoptosis.
Conclusions:
- NFAT2 plays a critical role in promoting lung cancer cell proliferation and carboplatin resistance.
- Targeting NFAT2 presents a promising strategy to enhance carboplatin efficacy in lung cancer treatment.
Related Concept Videos
Treatment Resistant Cancers
Binet's Contribution to Measures of Intelligence
Wechsler's Contribution to Measures of Intelligence
Lung Capacity
Resistivity
Resistance

